Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate.
Aiming to evaluate the efficacy of the treatment of canine visceral leishmaniasis, to verify the occurrence of a possible disease relapse, and to search for the presence of the parasites after the end of the treatment, seven dogs naturally infected by Leishmania (Leishmania) chagasi were used. The dogs were subjected to a treatment with 75 mg/kg meglumine antimoniate subcutaneously every 12 h for 21 days, and followed-up for a period of 6 months. During the whole experimental period the animals wore deltamethrin collars and were kept in a screened kennel to avoid reinfection. Lymph node and bone marrow aspiration biopsy was carried out to search for the parasite at seven moments: before the treatment, 30, 60, 90, 120, 150 and 180 days after the start of the treatment. After the end of the experiment all dogs were humanely euthanized. Then, spleen and liver "imprints" and in vitro cultures were carried out to search for amastigote forms of the parasite. During the treatment all animals presented remission of symptoms. However, two dogs were observed to present new symptoms in the course of the experiment. At the end of the experiment, the presence of amastigote forms of the parasite was evidenced in five of the seven dogs. This enabled us to conclude that the treatment promoted clinical cure but did not eliminate the parasites completely.
Ikeda-Garcia
Fabiana Augusta
FA
Department of Clinics, Surgery and Animal Reproduction, School of Veterinary Medicine, UNESP, São Paulo State University, Rua: Clóvis Pestana n. 793, CEP 16050-680, Araçatuba, São Paulo, Brazil.
Lopes
Raimundo Souza
RS
Marques
Fábia Judice
FJ
de Lima
Valéria Marçal Félix
VM
Morinishi
Celina Kazue
CK
Bonello
Fábio Luís
FL
Zanette
Maurício Franco
MF
Perri
Sílvia Helena Venturoli
SH
Feitosa
Mary Marcondes
MM
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000662:veterinary; D004197:Disease Reservoirs / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000453:epidemiology; D004285:Dogs; D005260:Female; D007279:Injections, Subcutaneous / Q000662:veterinary; D007891:Leishmania / Q000187:drug effects / Q000254:growth & development; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000453:epidemiology / Q000662:veterinary*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate